Latest Biotech News

Akeso’s ivonescimab extended survival in squamous non-small cell lung cancer in a China-only Phase 3 program presented at ASCO. In Harmoni-6, the PD-1/VEGF bispecific plus chemotherapy reduced the...

AstraZeneca/az’s pipeline ADC candidate puxitatug samrotecan generated high response rates in B7-H4–selected endometrial cancer data shown at ASCO. In the Phase 1/2a BLUESTAR study (NCT05123482),...

Giredestrant, an oral selective estrogen receptor degrader (SERD), reduced recurrence risk across menopausal subgroups in ER+/HER2− early breast cancer in the lidERA Phase 3 trial results...

Autobahn Therapeutics received FDA Fast Track designation for elunetirom (ABX-002) as adjunctive treatment for bipolar depression. The company said the designation is intended to increase the...

Pfizer agreed to pay upfront and milestones totaling as much as $10.5 billion for a multi-asset oncology collaboration with Innovent Biologics. The deal sets Pfizer up for a 12-candidate antibody...

Signos raised $20 million to expand its glucose monitoring platform beyond diabetes into weight-loss applications. The company’s system pairs Dexcom’s over-the-counter CGM devices with an app that...

Chan Zuckerberg Initiative’s Biohub unveiled an AI-generated protein atlas, the ESM Atlas, expanding predicted protein structure coverage by more than a billion entries. Biohub said the database,...

BMG LABTECH highlighted how microplate readers and reporter assays support real-time microbiology workflows in pathogen studies at the University of Glasgow. In a discussion with microbiologist...

Revolution Medicines disclosed expanded Phase 3 results for daraxonrasib in patients with KRAS-mutant metastatic pancreatic cancer, reporting a median overall survival gain of 13.2 months across...

Akeso and Summit Therapeutics’ ivonescimab posted a statistically significant overall survival improvement versus a PD-1 inhibitor plus chemotherapy in Harmoni-6, a Phase 3 trial run entirely in...

The FDA granted Fast Track status to elunetirom (ABX-002) as an adjunctive treatment for depressive episodes associated with bipolar I or bipolar II disorder in adults, according to a May 26...

A busy June at the FDA includes 11 upcoming PDUFA dates, with at least eight new products and three label expansions awaiting decisions, according to a regulatory calendar overview. One of the...

Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program, the company said during an event tied to ASCO. Daraxonrasib remains...

Pfizer announced a multi-drug R&D collaboration with Innovent Biologics valued at $10.5 billion, targeting next-generation antibody-drug conjugates (ADCs) for targeted cancer therapies. The deal...

New data from the lidERA Phase 3 trial showed that adjuvant giredestrant, an investigational oral selective estrogen receptor degrader (SERD), cut recurrence risk across both premenopausal and...

B7-H4-directed antibody-drug conjugate puxitatug samrotecan (AZD8205) delivered a 47.1% confirmed objective response rate in B7-H4-expressing recurrent or progressive endometrial cancer in the...

Allogene Therapeutics announced that Zachary Roberts, currently executive vice president of R&D and chief medical officer, will succeed David Chang as president and CEO on July 1, and will also...

Signos raised $20 million to expand its glucose monitoring platform beyond diabetes by targeting weight loss, the company said. The approach combines an over-the-counter Dexcom CGM with an app...

Revolution Medicines delivered what oncologists described as “landscape-changing” data for daraxonrasib at ASCO, extending survival in second-line metastatic pancreatic cancer with...

Akeso and Summit’s ivonescimab extended survival in a China-based Phase 3 study in previously untreated squamous NSCLC, delivering a 34% risk reduction in death versus standard immunotherapy plus...